RT Journal Article
SR Electronic
T1 From Community Acquired Pneumonia to COVID-19: A Deep Learning Based Method for Quantitative Analysis of COVID-19 on thick-section CT Scans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20070219
DO 10.1101/2020.04.17.20070219
A1 Li, Zhang
A1 Zhong, Zheng
A1 Li, Yang
A1 Zhang, Tianyu
A1 Gao, Liangxin
A1 Jin, Dakai
A1 Sun, Yue
A1 Ye, Xianghua
A1 Yu, Li
A1 Hu, Zheyu
A1 Xiao, Jing
A1 Huang, Lingyun
A1 Tang, Yuling
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.17.20070219.abstract
AB Background Thick-section CT scanners are more affordable for the developing countries. Considering the widely spread COVID-19, it is of great benefit to develop an automated and accurate system for quantification of COVID-19 associated lung abnormalities using thick-section chest CT images.Purpose To develop a fully automated AI system to quantitatively assess the disease severity and disease progression using thick-section chest CT images.Materials and Methods In this retrospective study, a deep learning based system was developed to automatically segment and quantify the COVID-19 infected lung regions on thick-section chest CT images. 531 thick-section CT scans from 204 patients diagnosed with COVID-19 were collected from one appointed COVID-19 hospital from 23 January 2020 to 12 February 2020. The lung abnormalities were first segmented by a deep learning model. To assess the disease severity (non-severe or severe) and the progression, two imaging bio-markers were automatically computed, i.e., the portion of infection (POI) and the average infection HU (iHU). The performance of lung abnormality segmentation was examined using Dice coefficient, while the assessment of disease severity and the disease progression were evaluated using the area under the receiver operating characteristic curve (AUC) and the Cohen’s kappa statistic, respectively.Results Dice coefficient between the segmentation of the AI system and the manual delineations of two experienced radiologists for the COVID-19 infected lung abnormalities were 0.74±0.28 and 0.76±0.29, respectively, which were close to the inter-observer agreement, i.e., 0.79±0.25. The computed two imaging bio-markers can distinguish between the severe and non-severe stages with an AUC of 0.9680 (p-value< 0.001). Very good agreement (κ = 0.8220) between the AI system and the radiologists were achieved on evaluating the changes of infection volumes.Conclusions A deep learning based AI system built on the thick-section CT imaging can accurately quantify the COVID-19 associated lung abnormalities, assess the disease severity and its progressions.Key Results A deep learning based AI system was able to accurately segment the infected lung regions by COVID-19 using the thick-section CT scans (Dice coefficient ≥ 0.74).The computed imaging bio-markers were able to distinguish between the non-severe and severe COVID-19 stages (area under the receiver operating characteristic curve 0.968).The infection volume changes computed by the AI system was able to assess the COVID-19 progression (Cohen’s kappa 0.8220).Summary Statement A deep learning based AI system built on the thick-section CT imaging can accurately quantify the COVID-19 infected lung regions, assess patients disease severity and their disease progressions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by National Natural Science Funding of China (No.61801491), Natural Science Funding of Hunan Province (No.2019JJ50728) and The Research Program of the Hunan Health and Family Planning Commission (No.B20180393).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicableAUCarea under the receiver operating characteristic curveCIconfidence intervalCOVID-19coronavirus disease 2019POIportion of infectioniHUaverage infection Hounsfield unit